Idenix Pharma Says Interim Data Show Valopicitabine Effective in Midstage Hepatitis Study
CAMBRIDGE, Mass.-- Idenix Pharmaceuticals Inc. said Friday interim data from a midstage study showed its hepatitis C drug candidate suppressed the virus with a low rate of side effects after 24 weeks of treatment.
The protocol for the Phase IIb clinical trial was amended in March after patients in the higher dose portion of the study showed signs of gastrointestinal side effects. The study cut out the 800 milligram dosing and continued with 200-milligram and 400-milligram dosing levels, involving 173 patients.
The 24-week data showed that 68 percent of patients receiving valopicitabine in combination with a pegylated interferon achieved viral clearance. The full study will continue for another 24 weeks.
Idenix is collaborating with Novartis Pharma AG to develop the drug.
Shares of Idenix rose 9 cents to $9.97 on the Nasdaq in morning trading.
More on the pharmacology later in the morning!
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment